CureVac (NASDAQ:CVAC) Stock Price Up 9.1% – Here’s What Happened

CureVac (NASDAQ:CVAC)’s stock price traded up 9.1% during trading on Tuesday . The stock traded as high as $3.12 and last traded at $3.19. 481,439 shares changed hands during trading, a decline of 46% from the average session volume of 885,243 shares. The stock had previously closed at $2.92.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $16.00 price target on shares of CureVac in a research note on Friday, February 14th.

CureVac Stock Down 4.4 %

The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The stock’s fifty day simple moving average is $3.64 and its two-hundred day simple moving average is $3.20. The company has a market capitalization of $678.36 million, a price-to-earnings ratio of 5.51 and a beta of 2.53.

Institutional Trading of CureVac

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new position in shares of CureVac in the fourth quarter valued at $585,000. Two Sigma Investments LP acquired a new stake in shares of CureVac during the fourth quarter worth $391,000. Alyeska Investment Group L.P. lifted its holdings in shares of CureVac by 25.0% during the fourth quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company’s stock valued at $1,705,000 after purchasing an additional 100,000 shares during the last quarter. Jane Street Group LLC boosted its position in shares of CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after purchasing an additional 55,867 shares during the period. Finally, Northern Trust Corp increased its stake in CureVac by 98.1% in the 4th quarter. Northern Trust Corp now owns 60,100 shares of the company’s stock worth $205,000 after purchasing an additional 29,759 shares in the last quarter. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.